ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 866

High Rate and Bimodal Pattern of Severe Infection in a Selected ANCA Associated Vasculitis Cohort

Esra Aydın1, Bahtiyar Toz2, Burak Erer2, Mustafa Erelel3, Ahmet Gocmez4, Ahmet Gul5, Murat Inanc2, Lale Ocal5 and Sevil Kamali2, 1Department of Internal Medicine,, istanbul faculty of medicine, istanbul, Turkey, 2Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 3Department of Pulmonology, Istanbul University Istanbul Faculty of Medicine Department of Pulmonology, istanbul, Turkey, 4Department of Radiology, Istanbul University Istanbul Faculty of Medicine, istanbul, Turkey, 5Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: ANCA and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Vasculitis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

 

Background/Purpose : Increased rate of severe infection (SI) in patients who exposed to immunosuppressive drugs has been a well-known complication in inflammatory rheumatic diseases. However, there are few reports on SI complicating AAV course.

Methods: We retrospectively investigated the characteristics of “SI requiring hospitalization” in AAV patients with lung involvement who were previously included into a study evaluating lung damage. Data were collected from hospital records between 2000-2014. Demographics, data on infection investigation including blood, sputum and urine cultures, viral serology, PPD/QTB tests, procalcitonin, imaging and biopsy findings, comorbidites, vasculitis activity and damage scores, cumulative dose of glucocorticoid (GC), cyclophosphamide (CYC) and rituximab (RTX) were noted into a predefined protocol. Infections that could not be revealed by cultures but succesfully treated with antibiotics were categorized as unidentified (UI). We compared the demographic and clinical data, presence of comorbidities, initial BVAS and cumulative VDI scores and GC/CYC doses according to the presence of SI by Mann-Whitney U test.

Results: Fifty-one AAV patients with lung involvement (25 female) (40 GPA, 8 MPA, 3 e-GPA) who were diagnosed according to ACR and CHCC criteria were included into the study. Age at diagnosis and total duration of follow-up were as follows: 49 ± 13 years (med 51), 67 ± 52 mo (med 47). Lung (100%), kidney (78 %), ENT ( 72 %), nervous system (25 %) were the involved organs. ANCA positivity was 94% (66% cANCA/anti-PR3, 34% p-ANCA/anti-MPO). Initial BVAS and cumulative VDI scores were 22±7 (4-38) (med 23), 3,4±2,2 (0-9) (med 3), respectively. Twenty-nine relapses occurred in 15 (29%) patients. Cumulative dose of GC and CYC were 16±9 g (med 14), 17± 25 (med 6), respectively. RTX was used in 17 patients. Diabetes (18%), chronic kidney failure (25%) were the major comorbidities and 7% had ESRD. Influenza and pneumococcal vaccination and TMP-SMX prophylaxis were applied in one forth and two-thirds of AAV cohort, respectively. Five patients (10%) had neutropenia (4 severe, 1 moderate) and suffered from SI. Eightyseven SI noted in 25 (52%) patients. Identified and unidentified SI in AAV cohort were shown in Table-1. Recurrent SI occurred in 27% of pulmonary and 33% of non-pulmonary groups. SI was associated with relapse in 16%. Serum

procalcitonin level increased in 93% (3.5±16.5, med 0.26, (0.5-95)) of 33 AAV patients. SI proportion was found to be increased during the first six months (%35) and after the 60th month of follow-up (30%). There were no significant difference between the patients with or without SI according to the risk factors. 

Bacterial

(35%)

n=30

Pulmonary

M.tuberculosis (1), Klebsiella (3), Pseudomonas (6), S.pneumoniae (1), E.coli (3), S.marcescens (1)

Urinary 

E.coli (3),  S.marcescens (1), Acinetobacter spp. (1)

Catheter infection

MRCNS (1), MSSA (1)

Musculo-skeletal

S.aureus (1)-septic arthritis, Nocardia (1)-Muscle abscess

Peritonsillar abscess

Corynebacterium spp. (1)

Choroiditis

M.tuberculosis (1)

Fungal

(21%)

n=19

 

Pulmonary

Aspergillus (2)

Esophagitis

Candida albicans (15)

Otitis media

Aspergillus (1)

Urethritis

Candida albicans (1)

Viral

(9%)

n=8

Shingles

HZV (4)

Esophagitis

CMV (2), HZV (1)

Chorioretinitis

CMV (1)

Unidentified

(35%)

n=30

 

Pulmonary (21), Cellulitis (1), Oral mucositis (1), Tonsillitis (1), Sinusitis (2), Ventriculoperitoneal shunt infection (1), Epididymo-orchitis (1), Mesenteric lymphadenitis with intraabdominal infection (1), Pelvic inflammatory disease (1)

Conclusion: Prevalence of SI was high and had a bimodal pattern in the early and late phase of AAV. SI was found to have a high proportion of re-occurrence. SI complicated disease relapses in a small group of patients


Disclosure: E. Aydın, None; B. Toz, None; B. Erer, None; M. Erelel, None; A. Gocmez, None; A. Gul, None; M. Inanc, None; L. Ocal, None; S. Kamali, None.

To cite this abstract in AMA style:

Aydın E, Toz B, Erer B, Erelel M, Gocmez A, Gul A, Inanc M, Ocal L, Kamali S. High Rate and Bimodal Pattern of Severe Infection in a Selected ANCA Associated Vasculitis Cohort [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/high-rate-and-bimodal-pattern-of-severe-infection-in-a-selected-anca-associated-vasculitis-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-rate-and-bimodal-pattern-of-severe-infection-in-a-selected-anca-associated-vasculitis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology